EUCTR2015-003386-28-IT进行中（未招募）1 期
A phase Ib/II multi-arm study with venetoclax in combination withcobimetinib, and venetoclax in combination with idasanutlin in patients =60 years with relapsed or refractory acute myeloid leukemia who are noteligible for cytotoxic therapy - GH29914
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Age >= 60 years
- •- Histological confirmation of relapsed or refractory AML after prior antileukemic
- •therapy by WHO Classification
- •- Not eligible for cytotoxic therapies
- •- Ineligible for allogeneic stem cell transplant
- •- Life expectancy of at least 12 weeks
- •- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2
- •- Adequate liver and renal function
- •- For women of childbearing potential: agreement to remain abstinent
- •(refrain from heterosexual intercourse) or use contraceptive methods
- •- For men: agreement to remain abstinent (refrain from heterosexual
- •intercourse) or use contraceptive measures, and agreement to refrain
- •from donating sperm
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 120
排除标准
- •- Patients with acute promyelocytic leukemia (French-American-British
- •[FAB] class M3 AML)
- •- Known active central nervous system (CNS) involvement with AML at
- •study entry
- •- Prior exposure to Bcl-2 inhibitors, murine double minute 2 (MDM2)
- •antagonists or prior exposure to experimental treatment targeting Raf,
- •mitogen-activated protein kinase (MEK), or the mitogen-activated
- •protein kinase (MAPK) RAS/RAF/MEK/ERK MAPK pathway
- •- Positive for hepatitis C virus (HCV), hepatitis B surface antigen
- •(HBsAg) and known history of HIV, malignancy, active infection and
- •cardiovascular diseases (CVs)
- •- Received strong cytochrome (CYP) 3A inhibitors, moderate CYP3A
- •inhibitors, strong CYP3A inducers and moderate CYP3A inducers within 7
- •days prior to initiation of study treatment
- •- History of symptomatic Clostridium difficile infection within 1 month
- •prior to dosing
- •Additional phase specific exclusion criteria:
- •Phase Ib Dose Escalation Arm A (Venetoclax and Cobimetinib)
- •- History or evidence of retinal pathology on ophthalmologic examination
- •that is considered a risk factor for neurosensory retinal
- •detachment/central serous chorioretinopathy (CSCR), retinal vein
- •occlusion (RVO), or neovascular macular degeneration
- •- Left ventricular ejection fraction (LVEF) below institutional lower limit
- •of normal (LLN) or below 50%, whichever is lower
- •Phase Ib Dose-Escalation Arm B (Venetoclax and Idasanutlin):
- •Received the following within 7 days prior to the initiation of study
- •Strong CYP2C8 inhibitors or CYP2C8 substrates
- •OATP1B1/3 substrates
- •Received the following within 14 days prior to the initiation of study
- •Strong CYP2C8 inducers
- •- Received hormonal therapy (apart from luteinizing hormone releasing
- •hormone agonist/antagonist for prostate cancer and hormone replacement therapy) within 2 weeks prior to the first dose of study
- •- History of liver cirrhosis by radiologic, clinical or laboratory data, or
- •biopsy despite normal liver function tests
- •Phase II Expansion Arm A and Arm B:
- •- Received the following within 7 days prior to the initiation of study
- •Strong CYP2C8 inhibitors or CYP2C8 substrates
- •OATP1B1/3 substrates
- •- Received the following within 14 days prior to the initiation of study
- •Strong CYP2C8 inducers
- •- History or evidence of retinal pathology on ophthalmologic examination
- •that is considered a risk factor for neurosensory retinal
- •detachment/CSCR, RVO, or neovascular macular degeneration
- •- LVEF below institutional LLN or below 50%, whichever is lower
- •- Received hormonal therapy (apart from luteinizing hormone releasing
- •hormone agonist/antagonist for prostate cancer and hormone
- •replacement therapy) within 2 weeks prior to the first dose of study
- •- History of liver cirrhosis by radiologic, clinical or laboratory data, or
- •biopsy despite normal liver function tests replacement therapy) within 2 weeks prior to the first dose of study
- •- History of liver cirrhosis by radiologic, clinical or laboratory data, or
- 另有 9 项未显示
研究者
相似试验
进行中（未招募）
1 期
A Study of Venetoclax in combination with Cobimetinib and Venetoclax in combination with Idasanutlin in Patients aged >=60 years with Relapsed or Refractory Acute Myeloid Leukemia who are not eligible for Cytotoxic TherapyEUCTR2015-003386-28-FRF. Hoffmann-La Roche Ltd140
招募中
2 期
A phase 2 study of venetoclax in combination with low-dose cytarabine in relapsing acute myeloid leukemiaCancer - Leukaemia - Acute leukaemiaAcute Myeloid LeukemiaACTRN12619000746134Alfred Hospital32
招募中
1 期
A phase Ib clinical evaluation of Venetoclax in combination with chemotherapy in older patients with Acute Myeloid LeukemiaAcute myeloid leukaemiaCancer - Leukaemia - Acute leukaemiaACTRN12616000445471Alfred Health48
尚未招募
Unknown
study of the combination of venetoclax, rituximab and lenalidomide for primary central nervous system lymphomaNeoplasmsKCT0008545Asan Medical Center52
进行中（未招募）
1 期
A Phase 1/2 Study of Venetoclax in Combination with Low-Dose Cytarabine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are = 60 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction TherapyAcute Myelogenous LeukemiaMedDRA version: 20.0Level: LLTClassification code 10001941Term: AMLSystem Organ Class: 100000004864EUCTR2014-002610-23-DEAbbVie Deutschland GmbH & Co. KG91